Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 10/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | CHKB | Q9Y259 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144451 | 0.93 | LMNA (0.41) | PNPLMNATP53ALDH1A1MAPT | |
| SCHEMBL11981806 | 0.83 | PIK3CD (0.46) | PNPLMNATP53ALDH1A1MAPT | |
| SCHEMBL337032 | 0.83 | PIK3CD (0.46) | PNPLMNATP53ALDH1A1MAPT | |
| SCHEMBL17144080 | 0.83 | PIK3CD (0.46) | PNPLMNATP53ALDH1A1MAPT | |
| SCHEMBL775864 | 0.82 | PIK3CA (0.49) | PNPADORA3 | |
| SCHEMBL30332447 | 0.78 | LMNA (0.50) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL786767 | 0.78 | LMNA (0.50) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1913691 | 0.78 | HCAR1 (0.48) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL30677299 | 0.78 | HCAR1 (0.48) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL17143823 | 0.77 | HCAR1 (0.45) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336132-B1 | MORPHOLINOPURINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PNP 97/4885LMNA 4352/4885TP53 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.